(Q38596011)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26423407%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

title

Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26423407%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

main subject

cardiovascular disease

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26423407%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

R Martin-Iguacel

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26423407%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

J M Llibre

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26423407%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

publication date

1 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26423407%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

published in

Current HIV/AIDS reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26423407%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26423407%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

375-387

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26423407%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26423407%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11904-015-0284-6

25 February 2020

exact match

0 references

cites work

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

HIV infection and the risk of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

HIV status and the risk of ischemic stroke among men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Increased coronary vessel wall thickness in HIV-infected young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Associations between HIV infection and subclinical coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Carotid intima media thickness is associated with body fat abnormalities in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Echocardiography and carotid intima-media thickness among asymptomatic HIV-infected adolescents in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Efficacy of contact lens systems against recent clinical and tap water Acanthamoeba isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 result

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Reduced platelet hyperreactivity and platelet-monocyte aggregation in HIV-infected individuals receiving a raltegravir-based regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Microbial translocation and cardiometabolic risk factors in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

C-reactive protein predicts 96-week carotid intima media thickness progression in HIV-infected adults naive to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Impact of HIV infection and HAART on serum lipids in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

HIV infection and high density lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

HIV Replication and Immune Status Are Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected Individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Associations between immune depression and cardiovascular events in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

CD4 decline is associated with increased risk of cardiovascular disease, cancer, and death in virally suppressed patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Epidemiology and management of antiretroviral-associated cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Ischemic Heart Disease in HIV-Infected and HIV-Uninfected Individuals: A Population-Based Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Protease inhibitors and cardiovascular outcomes in patients with HIV-1

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

21 January 2018

12 December 2020

Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Abacavir and increased risk of myocardial infarction – Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-015-0284-6

Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir

21 January 2018

1 reference

12 December 2020

Coronary heart disease in HIV-infected individuals

1 reference

12 December 2020

Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy

1 reference

12 December 2020

Can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools?

1 reference

12 December 2020

Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy

1 reference

12 December 2020

Abacavir and increased risk of myocardial infarction

1 reference

12 December 2020

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

1 reference

12 December 2020

Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection

1 reference

12 December 2020

Inflammation, coagulation and cardiovascular disease in HIV-infected individuals

1 reference

12 December 2020

Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease

1 reference

12 December 2020

Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada

1 reference

12 December 2020

LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy

1 reference

12 December 2020

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

12 December 2020

Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis

1 reference

12 December 2020

Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort

1 reference

12 December 2020

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

1 reference

12 December 2020

Predictors of hypertension and changes of blood pressure in HIV-infected patients.

1 reference

12 December 2020

Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database

1 reference

12 December 2020

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

1 reference

12 December 2020

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

1 reference

12 December 2020

Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons.

1 reference

12 December 2020

Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients

1 reference

12 December 2020

Sudden cardiac death in patients with human immunodeficiency virus infection

1 reference

12 December 2020

10.1007/S11904-015-0284-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26423407%20AND%20SRC:MED&resulttype=core&format=json

release_llodtsqgwnha5npb3djopxczhy

25 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/llodtsqgwnha5npb3djopxczhy

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26423407%20AND%20SRC:MED&resulttype=core&format=json